King's College London
- Country
- 🇸🇪Sweden
- Ownership
- Private
- Established
- 1829-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.kcl.ac.uk
Clinical Trials
724
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (559 trials with phase data)• Click on a phase to view related trials
RTSS Adoption Into Physiotherapists Documentation
- Conditions
- RehabilitationClinical ReasoningMedical Record Documenation
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- King's College London
- Target Recruit Count
- 16
- Registration Number
- NCT07038694
Sound Origins Acceptability Study
- Conditions
- Accessibility and Acceptability of Intervention
- First Posted Date
- 2025-06-15
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- King's College London
- Target Recruit Count
- 132
- Registration Number
- NCT07021469
- Locations
- 🇬🇧
Kings College London, London, Professor, United Kingdom
🇬🇧University College London Hospital Neonatal Unit, London, United Kingdom
Monitoring Arm Recovery After Stroke (MARS)
- Conditions
- Stroke
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- King's College London
- Target Recruit Count
- 30
- Registration Number
- NCT07016295
- Locations
- 🇬🇧
Centre for Human and Applied Physiological Sciences, London, United Kingdom
Can Dental Dedicated MRI Replace Low-dose CBCT Scanning in Dentistry
- Conditions
- Dental Situations
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- King's College London
- Target Recruit Count
- 20
- Registration Number
- NCT07008014
Purrble's Soothing Touch for Eating Disorders and Autism
- Conditions
- Eating DisordersAutism Spectrum Disorder
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- King's College London
- Target Recruit Count
- 200
- Registration Number
- NCT07007481
- Locations
- 🇬🇧
South London and Maudsley NHS Foundation Trust, London, United Kingdom
- Prev
- 1
- 2
- 3
- 4
- 5
- 92
- Next
News
AI-Guided Drug Discovery Identifies Promising Cancer Treatment Combinations Using Existing Non-Cancer Medications
University of Cambridge researchers used GPT-4 to identify drug combinations that could treat cancer, finding that three of 12 AI-suggested combinations outperformed current breast cancer drugs in laboratory tests.
Safety Concerns Emerge for Gold-Based Cisplatin Mimics in Cancer Treatment Development
Researchers from King's College London and Jagannath University discovered that gold-based cisplatin mimics contain a mixture of potentially dangerous isomers rather than a pure compound as previously believed for over 60 years.
Mindfulness-Based Cognitive Therapy Shows Promise for Treatment-Resistant Depression
A new clinical trial published in Lancet Psychiatry demonstrates that mindfulness-based cognitive therapy (MBCT) significantly improves symptoms in patients with difficult-to-treat depression compared to standard care.
Ubrogepant Shows Promise in Treating Migraine Prodromal Symptoms in Phase III Trial
A phase III clinical trial reveals that ubrogepant, an approved migraine medication, can effectively alleviate debilitating prodromal symptoms like fatigue, light sensitivity, and concentration difficulties that precede migraine headaches.
New Bone Marrow Test Could Double Survival Rates for Acute Myeloid Leukemia Patients
A groundbreaking UK trial has developed a highly sensitive bone marrow test that can detect returning Acute Myeloid Leukemia up to three months earlier than standard blood tests, potentially doubling survival rates for some patients.
Wegovy Shows Promise in Treating MASH, a Serious Liver Disease
A landmark Phase 3 clinical trial led by VCU and King's College London researchers found semaglutide significantly reduces liver inflammation and scarring in patients with metabolic dysfunction-associated steatohepatitis (MASH).
Lupus Research Alliance Awards $4.5 Million to Pioneer Next-Generation Cell Therapies for Lupus
The Lupus Research Alliance has launched its Targeted Research Program on Engineered Cell Therapies for Lupus (TRP-ECT), awarding grants to 11 researchers developing innovative cellular treatments.
NHS Launches £10 Million Clinical Trial on Puberty Blockers Following Cass Review Recommendations
The NHS has approved a £10.7 million clinical trial to investigate the potential benefits of puberty blockers for young people with gender dysphoria, following recommendations from Baroness Cass's comprehensive review.
JAK Inhibitors Reduce Thromboembolic Risk in Myeloproliferative Neoplasms Through Novel Mechanisms
A meta-analysis of 23 publications involving 2,198 patients demonstrated that JAK inhibitors significantly reduce thromboembolic events by 48% in myeloproliferative neoplasm patients, with ruxolitinib showing a 59% reduction in polycythemia vera and myelofibrosis.
Medtronic's GI Genius AI System Enters Large-Scale NAIAD Clinical Trial for Enhanced Colorectal Cancer Detection
Medtronic's GI Genius, an AI-powered tool, aims to improve the detection of precancerous lesions during colonoscopy screenings, crucial for early colorectal cancer treatment.